North America psychedelic drugs market is projected to register a CAGR of 15.8% in the forecast period of 2020 to 2027. The new market report contains data for the historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027.
Market Segmentation:
North America Psychedelic Drugs Market By Source (Synthetic, Natural), Type (Dissociatives, Empathogens, Serotonergic (Classical Psychedelic Drugs), Application (Narcolepsy, Treatment-Resistant Depression, Post-Traumatic Stress Disorder (PTSD), Major Depressive Disorder, Others), Route of Administration (Oral, Intranasal, Parenteral, Others), Drugs (Gamma Hydroxybutyric Acid (GHB), Ketamine, 3,4-Methylenedioxymethamphetamine (Ecstasy), Psilocybin), End User (Hospitals, Speciality Clinic, Research Organization, Others), Distribution Channel (Hospital Pharmacy, Compounding Pharmacy, Others), Country (U.S., Canada, Mexico) Industry Trends and Forecast to 2027
Some of the major factors contributing to the growth of North America psychedelic drugs market are:

• Increased acceptance of psychedelic drugs for the treatment of depression
• Rising incidence of depression and mental disorders in the region
Market Players:

The key market players for North America psychedelic drugs market are listed below:

• Johnson & Johnson Services, Inc.
• Jazz Pharmaceuticals, Inc.
• Celon Pharma SA
• COMPASS
• usonainstitute.org
• Develco pharma schweiz ag
• Doughlas pharmaceuticals limited
• NeuroRX, Inc.
• Hikma Pharmaceuticals PLC
• Amneal Pharmaceuticals, LLC.
• AVADEL PHARMACEUTICALS, PLC